Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al
Upcoming catalyst events the order and 6ming of expected GLP-1 and other clinical outcomes in weight loss/obesity to be announced
Helps with appetite control : Lower doses can assist in curbing cravings and support more careful eating habits
Some attenuation in HR was observed, but the impact of triple combination therapy on MACE, HHF, and CKD progression was still consistent, assuming 50% additivity
A: Possibly with a plan
As Blyumin put it, they were given limited use authorizations to compound these drugs that otherwise they shouldnt be able to, because theyre on patent. Now, those shortages have ended, and compounding pharmacies no longer have a legal basis for producing identical copies of GLP-1s